The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Expression of transforming growth factor-β isoforms in human glomerular diseases
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Self-citationEdwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, A. J., Angel, P., & Heath, J. K. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02449.x · Cited by 1,221
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346371a0 · Cited by 988
Self-citationTubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage
Nath, K. A. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80312-x · Cited by 974
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. (1992) · Nature · doi:10.1038/360361a0 · Cited by 974
Self-citationYamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E., & Border, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1814 · Cited by 830
Self-citationRenal Disease. Classification and Atlas of Glomerular Diseases.
(1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-801_2 · Cited by 672
Sanderson, N., Factor, V, Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., Roberts, A. B., Sporn, M. B., & Thorgeirsson, S. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2572 · Cited by 671
Pelton, R. W., Saxena, B., Jones, M., Moses, H. L., & Gold, L. I. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.1091 · Cited by 670
Self-citationRisdon, R. A., Sloper, J. C., & De Wardener, H. E. (1968) · The Lancet · doi:10.1016/s0140-6736(68)90589-8 · Cited by 668
Cited by
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
TGF-β/Smad signaling in renal fibrosis
Meng, X.-M., Tang, P. M.-K., Li, J., & Lan, H. Y. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00082 · Cited by 666
Extracellular Matrix Metabolism in Diabetic Nephropathy
Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 655
Branton, M. H., & Kopp, J. B. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00250-6 · Cited by 603
TGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
Expression of connective tissue growth factor in human renal fibrosis
Ito, Y., Aten, J., Bende, R. J., Oemar, B. S., Rabelink, T. J., Weening, J. J., & Goldschmeding, R. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00820.x · Cited by 562
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
Isaka, Y., Brees, D. K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N. A., & Border, W. A. (1996) · Nature Medicine · doi:10.1038/nm0496-418 · Cited by 482
Self-citationOldfield, M. D., Bach, L. A., Forbes, J. M., Nikolic-Paterson, D., McRobert, A., Thallas, V., Atkins, R. C., Osicka, T., Jerums, G., & Cooper, M. E. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11951 · Cited by 472
Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Border, W. A., & Noble, N. A. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.181 · Cited by 447
Self-citationThe Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D. (2010) · Diabetes · doi:10.2337/db09-1342 · Cited by 440
TGF-β in kidney fibrosis: A target for gene therapy
Border, W. A., & Noble, N. A. (1997) · Kidney International · doi:10.1038/ki.1997.190 · Cited by 379
Self-citationSchrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
Transforming growth factor‐β and Smad signalling in kidney diseases: Review Article
WANG, W., KOKA, V., & LAN, H. Y. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00334.x · Cited by 347
TGF-β signal transduction and mesangial cell fibrogenesis
Schnaper, H. W., Hayashida, T., Hubchak, S. C., & Poncelet, A.-C. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00300.2002 · Cited by 311
The role of EMT in renal fibrosis
Carew, R. M., Wang, B., & Kantharidis, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1227-1 · Cited by 294
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Dellas, C., & Loskutoff, D. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0033 · Cited by 285
Transforming growth factor- and the progression of renal disease
Loeffler, I., & Wolf, G. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft267 · Cited by 275
Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
Voelker, J., Berg, P. H., Sheetz, M., Duffin, K., Shen, T., Moser, B., Greene, T., Blumenthal, S. S., Rychlik, I., Yagil, Y., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111230 · Cited by 275
Regulation and Physiological Roles of Serum- and Glucocorticoid-Induced Protein Kinase Isoforms
Lang, F., & Cohen, P. (2001) · Science's STKE · doi:10.1126/stke.2001.108.re17 · Cited by 274
Estrogen-induced cardiorenal protection: potential cellular, biochemical and molecular mechanisms.
Dubey, R. K., & Jackson, E. K. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.3.f365 · Cited by 263
“Finally, recent studies from our laboratory provide evidence that 2-hydroxyestradiol and 2-methoxyestradiol are more potent than estradiol in inhibiting serum-induced growth of GMCs (302a), suggesting that the antimitogenic and glomeruloprotective effects of estradiol can also be mediated via its metabolites.”
BackgroundInfluentialChen, S., Jim, B., & Ziyadeh, F. N. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00132-3 · Cited by 256
Noh, H., Oh, E. Y., Seo, J. Y., Yu, M. R., Kim, Y. O., Ha, H., & Lee, H. B. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00086.2009 · Cited by 254
αvβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport Mouse
Hahm, K., Lukashev, M. E., Luo, Y., Yang, W. J., Dolinski, B. M., Weinreb, P. H., Simon, K. J., Chun Wang, L., Leone, D. R., Lobb, R. R., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060158 · Cited by 190
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Metadata
- Authors
- Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1996-02
- Volume
- 49
- Issue
- 2
- Pages
- 461-469
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2009729476
- Cited by
- 418
- References
- 47
- FWCI
- 25.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.